Immunogenicity of a first dose of mRNA- or vector-based SARS-CoV-2 vaccination in dialysis patients: a multicenter prospective observational pilot study

Paul Lesny1 · Mark Anderson2 · Gavin Cloherty2 · Michael Stec2 · Anja Haase-Fielitz3,4,5,6 · Mathias Haarhaus7,8 · Carla Santos7,9 · Carlos Lucas7 · Fernando Macario7 · Michael Haase1,7,10

Received: 10 May 2021 / Accepted: 18 May 2021 / Published online: 29 May 2021 © The Author(s) 2021

Abstract
Background Dialysis patients are at risk for lower SARS-CoV-2-vaccine immunogenicity than the normal population. We assessed immunogenicity to a first mRNA- or vector-based SARS-CoV-2-vaccination dose in dialysis patients.

Methods In a multicenter observational pilot study, 2 weeks after a first vaccination (BNT162b2/Pfizer-BioNTech [Comirnaty] or ChAdOx1 nCoV-19/Oxford-Astra-Zeneca [Vaxzevria]), hemodialysis patients (N = 23), peritoneal dialysis patients (N = 4) and healthy staff (N = 14) were tested for SARS-CoV-2-spike IgG/IgM, Nucleocapsid-protein-IgG-antibodies and plasma ACE2-receptor-binding-inhibition capacity. Hemodialysis patients who had had prior COVID-19 infection (N = 18) served as controls. Both response to first SARS-CoV-2 vaccination and IgG spike-positivity following prior COVID-19 infection were defined as SARS-CoV-2 spike IgG levels ≥ 50 AU/mL.

Results Vaccination responder rates were 17.4% (4/23) in hemodialysis patients, 100% (4/4) in peritoneal dialysis patients and 57.1% (8/14) in staff (HD vs. PD: p = 0.004, HD vs. staff: p = 0.027). Among hemodialysis patients, type of vaccine (Comirnaty N = 11, Vaxzevria N = 12, 2 responders each) did not appear to influence antibody levels (IgG spike: Comirnaty median 0.0 [1.–3. quartile 0.0–3.8] versus Vaxzevria 4.3 [1.6–20.1] AU/mL, p = 0.079). Of responders to the first dose of
SARS-CoV-2 vaccination among hemodialysis patients (N = 4/23), median IgG spike levels and ACE2-receptor-binding-inhibition capacity were lower than that of IgG spike-positive hemodialysis patients with prior COVID-19 infection (13/18, 72.2%): IgG spike: median 222.0, 1.–3. quartile 104.1–721.9 versus median 3794.6, 1.–3. quartile 793.4–9357.9 AU/mL, p = 0.015; ACE2-receptor-binding-inhibition capacity: median 11.5%, 1.–3. quartile 5.0–27.3 versus median 74.8%, 1.–3. quartile 44.9–98.1, p = 0.002.

**Conclusions** Two weeks after their first mRNA- or vector-based SARS-CoV-2 vaccination, hemodialysis patients demonstrated lower antibody-related response than peritoneal dialysis patients and healthy staff or unvaccinated hemodialysis patients following prior COVID-19 infection.

**Graphic abstract**

**Immunogenicity of a 1st dose of mRNA- or vector-based SARS-CoV-2 vaccination in dialysis patients**

**1st vaccination dose** 2 weeks

**Vaccinated participants**
- 23 hemodialysis patients
- 4 peritoneal patients
- 14 healthy staff

**Participants after COVID-19**
- 18 hemodialysis patients

**Measurements**
- IgG and IgM spike
- IgG Nucleocapsid
- ACE2 receptor binding inhibition

**Findings** After first mRNA- or vector-based vaccine dose, responder rates, antibody levels and neutralizing capacity were low in hemodialysis patients and staff.

**Keywords** mRNA- or vector-based SARS-CoV-2 vaccination · Responder · Hemodialysis · Peritoneal dialysis · COVID-19 · ACE2 receptor binding inhibition capacity

**Introduction**

Several two-dose SARS-CoV-2 vaccines have been approved to prevent COVID-19 infection, with a reported vaccine efficacy of 90–95% in the normal population after the second dose. Dialysis patients are at high risk for COVID-19 infection and mortality [1, 2] but were not included in the vaccination registration trials. Small observational studies showed a sufficient immune response several weeks after the second SARS-CoV-2 mRNA-based vaccination [3, 4]. However, no study compared the effect of a first mRNA-based vaccination with that of a vector-based vaccination on antibody response in hemodialysis patients.

In a pilot study, we aimed to assess the antibody-related immunogenicity of a first dose of mRNA- or vector-based SARS-CoV-2 vaccine in this patient population compared to that of peritoneal dialysis patients, staff and unvaccinated hemodialysis patients who had had a prior COVID-19 infection.

**Methods**

**Design, setting and participants**

In a multicenter, prospective, observational pilot study, we tested blood antibody levels to the SARS-CoV-2 Spike (S-protein) and nucleocapsid (N-protein) proteins in hemodialysis, peritoneal dialysis, or healthy control populations (health care workers/staff) at the Diaverum Renal Care
Centers Potsdam, Ludwigsfelde and Rangsdorf, receiving the BNT162b2/Pfizer-BioNTech (Comirnaty) or ChAdOx1 nCoV-19/Oxford-Astra-Zeneca (Vaxzevria) vaccine, and in hemodialysis patients having previously presented with PCR-positive COVID-19. Approval was obtained from the Ethics Committee of ‘Landesärztekammer Brandenburg’, Germany (registry number S9/(bB)/2021). The procedures used in this study adhere to the tenets of the Declaration of Helsinki. Written informed consent to participate and publish was obtained from all individual study participants. Information regarding clinical data was collected from medical records. Healthy controls provided demographic data. This manuscript adheres to the ‘Strengthening the Reporting of Observational Studies in Epidemiology’ guidelines [5].

SARS-CoV-2 antibodies and ACE2-receptor-binding-inhibition capacity

Participant plasma was collected at baseline and 2 weeks after receiving a first vaccine dose. Participants were tested for SARS-CoV-2 IgG and IgM antibodies directed against the S-protein, and IgG antibodies directed against the SARS-CoV-2 N-protein. All samples were run on Abbott ARCHITECT™ i2000SR instrument (Abbott Park, IL). The FDA EUA approved SARS-CoV-2 IgG (List 6R86), AdviseDx SARS-CoV-2 IgM (List 6R87), and SARS-CoV-2 IgG II Quant (List 6S60) assays were used, both automated Chemiluminescent Microparticle Immunoassays (CMIA). Assay results are reported as an index value of the ratio of specimen to calibrator Relative Light Units (RLU) signal. The SARS-CoV-2 IgG II Quant assay is an automated CMIA used for quantitative detection of IgG antibodies directed against the receptor-binding-domain of the SARS-CoV-2 S-protein. Assay linearity was shown between 21.0 and 40,000 AU/mL. A Research Use Only automated CMIA assay measured the capacity of SARS-CoV-2 antibodies, present in participant plasma, to inhibit SARS-CoV-2 receptor-binding-domain from binding to ACE2-receptors. The laboratory investigators were blinded to the sample sources and clinical outcomes. Researchers who obtained clinical data were blinded to antibody measurements.

Study endpoints

SARS-CoV-2 spike IgG, IgM and Nucleocapsid IgG levels (AU/mL) and ACE2-receptor-binding-inhibition capacity (%) were provided as linear variables. Both response to the first SARS-CoV-2 vaccination and antibody level positivity following prior COVID-19 infection were defined as SARS-CoV-2 spike IgG levels ≥ 50 AU/mL.

Statistical analysis

Study size was determined by the first badge of antibody measurements to gather early potentially important clinical information for this patient population. Values are presented as median (1.–3. quartile). Antibody levels and response status were compared: (i) hemodialysis patients receiving the mRNA-based SARS-CoV-2 vaccination vs. hemodialysis patients receiving the vector-based vaccine, (ii) vaccinated hemodialysis patients versus hemodialysis patients following prior COVID-19 infection, (iii) vaccinated hemodialysis versus peritoneal patients and (iv) vaccinated hemodialysis patients versus staff. Mann–Whitney-U-test, χ² test, or Fisher’s exact test were used where appropriate. Alpha was set at 0.05 (2-tailed). SPSS, version 26.0 (IBM Corp., Armonk, NY, USA) was used.

Results

Participant characteristics

The 59 participants enrolled in the study included 41 individuals receiving regular hemodialysis, four on peritoneal dialysis, and 14 staff (Fig. 1). Of the hemodialysis patients, 23 received a first dose of the SARS-CoV-2 vaccine (Comirnaty N = 11, Vaxzevria N = 12) and had no recent COVID-19 infection, whereas 18 had a history of COVID-19 but did not receive a SARS-CoV-2 vaccine. Table 1 summarizes the demographic information of vaccinated hemodialysis patients regarding the SARS-CoV-2 vaccine, antibody levels and neutralization capacity before vaccination, previous vaccinations/immunosuppression, dialysis characteristics, comorbidities, medication and routine laboratory values. In other words, a typical cohort with considerable comorbidity and evidence of immunosuppression but with no significant antibody levels against SARS-CoV-2 prior to vaccination.

Peritoneal dialysis patients were aged 60 (52–79) years (all females, one Comirnaty/three Vaxzevria). All staff received Vaxzevria (age 54, [35–56] years, 13 females).

Time from first vaccination to sampling was 14 (13–16) days for hemodialysis patients, 17.5 (13.3–21.0) days for peritoneal dialysis patients and 14 (14–17.5) days for staff.

Time from diagnosis of prior COVID-19 infection to sampling was 6 months (2.5–12.0).

Effect of 1st vaccination in hemodialysis patients versus peritoneal dialysis patients and staff

None of the vaccinated hemodialysis or peritoneal patients or staff was positive for the IgG Nucleocapsid-protein, indicating immunity did not result from a recent COVID-19 infection. Vaccination responder rates were 17.4%
(4/23) in hemodialysis patients, 100% (4/4) in peritoneal dialysis patients and 57.1% (8/14) in staff (HD vs. PD: p = 0.004, HD vs. staff: p = 0.027).

Figure 2 shows lower IgG and IgM spike levels in first vaccinated hemodialysis patients compared to the levels in peritoneal dialysis patients and staff (IgG spike: HD 1.6 [0–14.5] vs. PD 180.7 [82.5–241.9] AU/mL, p = 0.011; HD versus staff 73.1 [16.1–1324.5] AU/mL, p < 0.001, missing values N = 0). ACE2-receptor-binding-inhibition capacity was low in vaccinated hemodialysis (5.0% [3.1–10.4]) and peritoneal dialysis patients (12.9% [9.6–19.8]) and in staff (10.5% [6.0–40.9]), as well as in hemodialysis patients responding to vaccination (11.5% [5.0–27.3]).

**Effect of mRNA- versus vector-based SARS-CoV-2 vaccine in hemodialysis patients**

Time from vaccination to sampling was 13.0 (13.0–16.0) days for Comirnaty (N = 11) and 14.5 (14.0–16.8) days for Vaxzevria (N = 12), with two responders to each vaccination. Type of vaccine did not appear to influence the antibody levels of hemodialysis patients (Fig. 3A,B; missing values N = 0). ACE2-receptor-binding-inhibition was 3.8% (1.1–11.3) in hemodialysis patients receiving Comirnaty and 7.1% (3.8–14.9) in those receiving Vaxzevria.

**First vaccinated hemodialysis patients versus hemodialysis patients with previous COVID-19 infection**

Of the 18 hemodialysis patients with prior COVID-19 infection, 15 were positive for the IgG Nucleocapsid-protein. IgM spike levels were 0.86 (0.03–7.46) and Nucleocapsid-protein Index levels were 3.0 (1.4–6.0).

Of the hemodialysis patients with prior COVID-19 infection, those with IgG spike-positivity (13/18, 72.2%) had higher IgG spike levels and ACE2-receptor-binding-inhibition capacity compared with that of first dose vaccination-responding hemodialysis patients (N = 4/23): IgG spike: 3,794.6 (793.4–9357.9) vs. 222.0 (104.1–721.9) AU/mL, p = 0.015; ACE2-receptor-binding-inhibition capacity: 74.8% (44.9–98.1) vs. 11.5% (5.0–27.3), p = 0.002.

**SARS-CoV-2 IgG spike levels and ACE2-receptor-binding-inhibition capacity**

There was high correlation between reported IgG spike levels and ACE2-receptor-binding-inhibition capacity (Spearman correlation coefficient r = 0.89, p < 0.001).
| Table 1  | Baseline characteristics | Hemodialysis patients after 1st mRNA- or vector-based SARS-CoV-2 vaccination |
|----------|--------------------------|------------------------------------------------------------------|
|          | N = 23                   |                                                                  |
| Age      | 64 (61–83)               |                                                                  |
| Female   | 8 (34.8%)                |                                                                  |
| Vintage (months) | 26 (13–50)            |                                                                  |
| Body mass index (kg/m²) | 27.5 (25.3–30.8)    |                                                                  |
| Nursing home | 2 (8.7%)                |                                                                  |
| Disability | 4 (17.4%)                |                                                                  |
| Tobacco use | 1 (4.4%)                |                                                                  |
| Alcohol use disorder | 3 (13.0%)                |                                                                  |
| Drug abuse disorder | 0 (0%)                |                                                                  |
| SARS-CoV-2 vaccination-related information | | |
| 1st SARS-CoV-2 vaccination (comirnaty/vaxzevria) | 11 (47.8%)/12 (52.2%) | |
| Interval between 1st SARS-CoV-2 vaccination and sampling, days | 14 (13–16) | |
| Hospitalization within 14 days after 1st SARS-CoV-2 vaccination | 0 (0%) | |
| Antibody levels and neutralization capacity before vaccination | | |
| IgG spike, AU/mL | 0.0 (0.0–0.8) | |
| IgM spike, index | 0.03 (0.02–0.04) | |
| IgG nucleocapsid, index | 0.05 (0.02–0.08) | |
| ACE2 receptor binding inhibition, % | 4.4 (3.1–5.9) | |
| Previous vaccinations or immunosuppression | | |
| Other vaccines within 14 days | 0 (0%) | |
| Time from previous vaccination to SARS-CoV-2 vaccination, months | 4.5 (2.8–5.0) | |
| Potential immunosuppression | 3 (13.0%) | |
| History of kidney transplantation | 5 (21.7%) | |
| Immunodeficiency disorder (other than kidney transplantation) | 3 (13.0%) | |
| Dialysis-related information | | |
| Charlson comorbidity index | 4.0 (3.0–5.5) | |
| Diabetic nephropathy | 3 (13.0%) | |
| Hypertensive kidney disease | 12 (52.2%) | |
| Glomerulonephritis | 2 (8.7%) | |
| Autosomal dominant polycystic kidney disease | 2 (8.7%) | |
| Other/unknown primary kidney disease | 4 (17.4%) | |
| Kt/V | 1.8 (1.5–2.0) | |
| Fistula | 17 (73.9%) | |
| Graft | 3 (13.0%) | |
| Central venous catheter | 3 (13.0%) | |
| Comorbidities | | |
| Number of comorbidities | 16 (13–21) | |
| Transplantation candidate | 13 (56.5%) | |
| Obesity (body mass index > 30) | 2 (8.7%) | |
| Diabetes mellitus | 6 (26.1%) | |
| Hypertension | 22 (95.7%) | |
| Ischemic heart disease | 8 (34.8%) | |
| Congestive heart failure | 8 (34.8%) | |
| Chronic obstructive disease | 4 (17.4%) | |
| Stroke/cerebrovascular disorder | 3 (13.0%) | |
| Peripheral vascular disease | 2 (8.7%) | |
| History of malignancy | 7 (30.4%) | |
Discussion

Two weeks after the first SARS-CoV-2 vaccine dose, we demonstrated a low responder rate and minimal neutralizing antibody levels in hemodialysis patients regardless of the type of vaccine. Following prior COVID-19 infection in hemodialysis patients, antibody-related immunity was more pronounced than that of responding first vaccinated hemodialysis patients. There was a strong correlation between SARS-CoV-2 IgG spike levels and ACE2-receptor-binding-inhibition capacity.

Notably, COVID-19 occurring in the normal population shortly after first vaccination has been described. A recent study reported that, as vaccination programs start to roll out, social distancing decreases due to the anticipated efficacy of SARS-CoV-2 vaccinations [6]. Recently, reduced antibody response after the first dose of mRNA-based COVID-19 vaccine in hemodialysis patients was briefly reported [7]. However, the effect of the first dose of a vector-based vaccine in hemodialysis patients remains unknown and peritoneal dialysis patients have not yet been investigated in this regard.

The findings of the present study are novel regarding the severely impaired quantitative and qualitative antibody-related response in hemodialysis patients 2 weeks after the first dose of both mRNA- and vector-based vaccines. To prevent new cases of COVID-19 between the first and second vaccination, our study findings suggest that SARS-CoV-2 protective measures should at least be sustained in dialysis patients and staff until the full effect of the second vaccination dose is achieved. Study results also imply that hemodialysis patients should not be considered for delayed second dose of vaccination. Our study might point toward more rapid vaccination response in peritoneal dialysis patients. The high antibody levels in patients with prior COVID-19 infection confirms previous findings in patients on maintenance dialysis who recovered from COVID-19 [8]. Whether this persistent immunity may predispose dialysis patients to a similar triggering effect of a single vaccine dose as described for other populations, remains to be studied [9]. The demonstrated strong association between IgG spike levels and ACE2-receptor-binding-inhibition elicited by a single vaccine dose in dialysis patients was previously shown in patients with COVID-19 [10] and may confirm assay usability in dialysis patients.

Table 1 (continued)

| Hemodialysis patients after 1st mRNA-or vector-based SARS-CoV-2 vaccination | N = 23 |
|---------------------------------|-------|
| Thyroid disorder                | 8 (34.8%) |
| Medications                     |       |
| Erythropoiesis stimulating agents dose (unit per week) | 4,000 (550–10,000) |
| Iron dose (mg/week)             | 40 (10–50) |
| Angiotensin blockers            | 12 (52.2%) |
| ACE inhibitors                  | 4 (17.4%) |
| Betablockers                    | 19 (82.6%) |
| Calcium antagonists             | 12 (52.2%) |
| Diuretics                       | 14 (60.9%) |
| Phosphate binders               | 13 (56.5%) |
| Insulin                         | 4 (17.4%) |
| Vitamin D                       | 17 (73.9%) |
| Active vitamin D                | 14 (60.9%) |
| Laboratory values               |       |
| Albumin g/L                     | 37 (33–41) |
| Hypoalbuminemia (albumin < 3.5 g/L) | 10 (43.5%) |
| Hemoglobin (g/dL)               | 11.1 (10.7–11.4) |
| Transferrin saturation (%)      | 25.0 (19.7–29.0) |
| Ferritin (mg/dL)                | 422 (271–484) |
| White blood cell count          | 5.9 (5.4–7.2) |
| C-reactive protein, ml/L        | 4 (2–10) |

SARS-CoV-2, severe acute respiratory syndrome coronavirus 2

*aMissing values N = 14*
Strengths and limitations

The generalizability of our study results is limited by the small patient number. Cell-related immunity was not measured. However, we report the findings of a prospective multicenter pilot study including results of a neutralizing antibody assay and have taken advantage of the use of different types of vaccinations in our hemodialysis patients. Furthermore, healthy staff after first vaccination dose and hemodialysis patients after COVID-19 infection were reported as control groups.

In conclusion, most hemodialysis patients and a considerable proportion of healthy staff exhibited an insufficient antibody-related response 2 weeks after a first mRNA- or vector-based SARS-CoV-2 vaccination, indicating the need to continue with protective measures. Patients with prior COVID-19 infection demonstrated a persistence of
SARS-CoV-2 spike-protein antibodies. Further studies with serial measurements of spike-protein antibodies are needed to determine whether this antibody persistence may result in a triggering effect of a single vaccine dose, thus potentially saving the need for a second dose in hemodialysis patients with prior COVID-19.

Acknowledgements We thank the staff of the Diaverum Renal Care Centers Potsdam, Ludwigsfelde and Rangsdorf for their excellent assistance.

Author contributions Conceptualization: PL, MH; Methodology: PL, MH; Formal analysis and investigation: MH, PL, MA, GC, MS, AH, MH, CS, CL, FM; Writing—original draft preparation: MH, AH; Writing—review and editing: PL, MH, AH, MA, GC, MS, MH, CS, CL, FM; Funding acquisition: MH, AH; Resources: PL, MH, AH; Supervision: PL, MH.

Funding Open Access funding enabled and organized by Projekt DEAL. Antibodies were measured by Abbott Laboratories and supported by Abbott’s internal Research and Development funding.

Availability of data and materials The datasets generated and/or analyzed during the current study are available from the corresponding author on reasonable request.

Declarations

Conflict of interest Mark Anderson, Gavin Cloherty, Michael Stec: Employee of Abbott Laboratories. The other authors declare no conflict of interest.
Ethics approval  The study was approved by the Ethics Committee of the ‘Landesärztekammer Brandenburg’, Germany (registry number S 9/(bB)/2021). The procedures used in this study adhere to the tenets of the Declaration of Helsinki. Written informed consent to participate and to publish was obtained from all individual participants included in the study.

Consent to participate  Written informed consent to participate was obtained from all individual participants included in the study.

Consent for publication  Written informed consent to publish was obtained from all individual participants included in the study.

Open Access  This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Quintaliani G, Reboldi G, Di Napoli A et al (2020) Exposure to novel coronavirus in patients on renal replacement therapy during the exponential phase of COVID-19 pandemic: survey of the Italian Society of Nephrology. J Nephrol 33:725–736. https://doi.org/10.1007/s40620-020-00794-1
2. Haarhaus M, Santos C, Haase M et al (2021) Risk prediction of COVID-19 incidence and mortality in a large multi-national hemodialysis cohort: implications for management of the pandemic in outpatient hemodialysis settings. Clin Kidney J 14:805–813. https://doi.org/10.1093/ckj/sfab037
3. Schrezenmeier E, Bergfeld L, Hillus D et al (2021) Immunogenicity of COVID-19 tozinameran vaccination in patients on chronic dialysis. medRxiv. https://doi.org/10.1101/2021.03.31.21254683
4. Grupper A, Sharon N, Finn T et al (2021) Humoral response to the Pfizer BNT162b2 vaccine in patients undergoing maintenance hemodialysis. Clin J Am Soc Nephrol. https://doi.org/10.2215/CJN.03500321
5. von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP (2014) The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Int J Surg 12:1495–1499. https://doi.org/10.1016/j.ijsu.2014.07.013
6. Andersson O, Campos-Mercade P, Meier A, Wengström E (2020) Anticipation of COVID-19 vaccines reduces social distancing. SSRN. https://doi.org/10.2139/ssrn.3765329
7. Torreggiani M, Blanchi S, Fois A, Fessi H, Piccoli GB (2021) Neutralizing SARS-CoV-2 antibody response in dialysis patients after the first dose of the BNT162b2 mRNA COVID-19 vaccine: the war is far from being won. Kidney Int. https://doi.org/10.1016/j.kint.2021.04.010
8. Ikizler TA, Coates PT, Rovin BH, Ronco P (2021) Immune response to SARS-CoV-2 infection and vaccination in patients receiving kidney replacement therapy. Kidney Int. https://doi.org/10.1016/j.kint.2021.04.007
9. Levi R, Azzolini E, Pozzi C et al (2021) One dose of SARS-CoV-2 vaccine exponentially increases antibodies in recovered individuals with symptomatic COVID-19. J Clin Investig. https://doi.org/10.1172/JCI149154
10. Ebinger JE, Fert-Bober J, Printsev I et al (2021) Antibody responses to the BNT162b2 mRNA vaccine in individuals previously infected with SARS-CoV-2. Nat Med. https://doi.org/10.1038/s41591-021-01325-6

Publisher’s Note  Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.